申请人:The DuPont Merck Pharmaceutical Company
公开号:US05635477A1
公开(公告)日:1997-06-03
This invention relates to novel cyclic compounds containing carbocyclic ring systems useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, with or without other therapeutic agents, and to methods of using these compounds, with or without other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of other thromboembolic disorders. This invention also relates to methods of using the cyclic compounds of the invention in combination with anti-coagulants such as warfarin or heparin, or additional anti-platelet agents such as aspirin, piroxicam or ticlopidine, or thrombin inhibitors such as boropeptides, hirudin or argatroban, or thrombolytic agents such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof, for the treatment of thromboembolic disorders. A representative compound of the invention is cyclo(D-Val-(.sup..alpha. N-methyl Arg)-Gly-Asp-(3-aminomethylbenzoic acid).
本发明涉及新型含环状化合物的抗血小板糖蛋白IIb/IIIa复合物拮抗剂,这些化合物含有碳环状系统,可用于制备药物组合物,包括这些环状化合物,与或不含其他治疗剂,以及使用这些化合物,与或不含其他治疗剂,用于抑制血小板聚集,作为溶栓剂和/或用于治疗其他血栓栓塞性疾病的方法。本发明还涉及使用本发明的环状化合物与抗凝剂(如华法林或肝素)或其他抗血小板剂(如阿司匹林、吡罗昔康或替克洛匹定)或凝血酶抑制剂(如硼肽、酶素或阿加曲班)或溶栓剂(如组织型纤溶酶原激活剂、安斯特雷普拉斯、尿激酶或链激酶)或其组合物,用于治疗血栓栓塞性疾病的方法。本发明的代表性化合物是环状D-Val-(.sup..alpha. N-甲基Arg)-Gly-Asp-(3-氨甲基苯甲酸)。